Sotatercept denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for sotatercept are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Sotatercept as Non-Formulary

Sotatercept is a recently approved specialty biologic for pulmonary arterial hypertension (PAH). Because it is a newer agent, UHC may not yet have placed it on your specific plan's formulary tier, or may have placed it at the highest specialty tier with the most restrictive criteria. A non-formulary denial does not mean the drug is clinically inappropriate — it means it has not been pre-positioned on your plan's preferred drug list for automatic coverage, which is an administrative status that can be overridden through a formulary exception or medical-necessity appeal.

## Your Appeal Rights

• Formulary exception request: Before filing a full appeal, ask UHC for a formulary exception. The prescribing specialist must submit a letter explaining why no formulary alternative is clinically appropriate for this patient's specific PAH profile. Plans are required under ACA rules to have a meaningful formulary exception process.
• Internal appeal (ACA §2719 / ERISA §503): If the formulary exception is denied, you have the right to a full internal appeal. Submit all supporting clinical documentation.
• Independent external review: After internal appeal denial, you may request external review by an accredited IRO — typically within approximately four months of the denial. The IRO applies clinical standards, not the plan's formulary placement.
• Expedited option: PAH is a serious, potentially life-threatening condition. If delay would cause serious deterioration, invoke expedited review rights.

## Documentation to Gather

1. Formulary alternative comparison: Obtain UHC's formulary alternatives list. Have the prescribing physician document in writing why each listed alternative is clinically inadequate, contraindicated, or already failed for this patient. 2. PAH diagnosis confirmation: Right-heart catheterization results, specialist evaluation confirming diagnosis and severity. 3. Treatment history: Dated records of prior PAH therapies tried, duration, and outcomes. 4. Prescriber letter: A letter from the PAH specialist explaining why sotatercept specifically is medically necessary and no formulary alternative is sufficient. 5. FDA label reference: The specialist letter should reference the FDA-approved indication — obtain the current prescribing information from the FDA label or manufacturer to confirm the exact approved use.

## Criteria-Mapping for the Exception Request

UHC's formulary exception form typically asks why the requested drug is medically necessary and why alternatives are not appropriate. Treat each question on the form as a criterion to be addressed explicitly. Pull the exact language of each formulary alternative from UHC's published formulary and have the physician address each by name. Vague answers — "patient cannot tolerate alternatives" — are far less effective than chart-documented specifics tied to each alternative.

## Key Point

Formulary placement is a plan-administrative decision; clinical appropriateness is a separate question. IROs consistently override non-formulary denials when the clinical record demonstrates the requested drug is appropriate and alternatives have failed or are not suitable. Build that record before submitting.